Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

被引：2

作者：

Harrington, Kevin Joseph

Kong, Anthony

Mach, Nicolas

Chesney, Jason Alan

Castelo, Beatriz

Rischin, Danny

Cohen, Ezra E. W.

Radcliffe, Hoi-Shen

Gumuscu, Burak

Snyder, Wendy

Siu, Lillian L.

机构：

[1] Royal Marsden Inst Canc Res NIHR Biomed Res Ctr, London, England

[2] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England

[3] Univ Hosp Geneva, Dept Oncol, Geneva, Switzerland

[4] Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA

[5] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain

[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[7] Univ Calif San Diego, San Diego, CA 92103 USA

[8] Amgen Inc, Uxbridge, Middx, England

[9] Merck & Co Inc, Kenilworth, NJ USA

[10] Amgen Inc, Thousand Oaks, CA 91320 USA

[11] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.6036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6036

引用

页数：3

共 50 条

[1] Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).
Harrington, Kevin J.
Kong, Anthony Hee
Mach, Nicolas
Rordorf, Tamara
Jaime, Jesus Corral
Espeli, Vittoria
Treichel, Sheryl
Gumuscu, Burak
Kim, Jenny J.
Chesney, Jason Alan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Harrington, Kevin J.
Kong, Anthony
Mach, Nicolas
Chesney, Jason A.
Fernandez, Beatriz Castelo
Rischin, Danny
Cohen, Ezra E. W.
Radcliffe, Hoi-Shen
Gumuscu, Burak
Cheng, Jonathan
Snyder, Wendy
Siu, Lillian L.
CLINICAL CANCER RESEARCH, 2020, 26 (19) : 5153 - 5161
[3] Early safety from phase 1b/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): MASTERKEY-232
Harrington, K.
Kong, A.
Mach, N.
Rordorf, T.
Corral, J.
Espeli, V.
Treichel, S.
Cheng, J.
Kim, J.
Chesney, J.
ANNALS OF ONCOLOGY, 2017, 28
[4] Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma
Dummer, Reinhard
Long, Georgina V.
Ribas, Antoni
Puzanov, Igor
Michielin, Olivier
VanderWalde, Ari
Andtbacka, Robert H. I.
Cebon, Jonathan
Fernandez, Eugenio
Malvehy, Josep
Olszanski, Anthony J.
Gajewski, Thomas F.
Kirkwood, John M.
Gause, Christine
Chen, Lisa
Kaufman, David R.
Chou, Jeffrey
Hodi, F. Stephen
JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
[5] A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).
Hecht, J. Randolph
Prat, Aleix
Pless, Miklos
Cubillo, Antonio
Calvo, Aitana
Raman, Steven
Chesney, Jason Alan
Liu, Chunxu
Chan, Emily
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] LONG-TERM ANALYSIS OF MASTERKEY-265 PHASE 1B TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) PLUS PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE STAGE IIIB-IVM1C MELANOMA
Long, Georgina
Dummer, Reinhard
Johnson, Douglas
Michielin, Olivier
Martin-Algarra, Salvador
Treichel, Sheryl
Chan, Edward
Diede, Scott
Ribas, Antoni
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A261 - A261
[7] Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line(1L) Pembrolizumab (pembro) plus Carboplatin (carbo) plus Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
Dzienis, M.
Cundom, J.
Fuentes, C. S.
Spreafico, A.
Nordlinger, M. J.
Pastor, A. V.
Alesi, E.
Neki, A.
Fung, A. S.
Lima, I. P. Figueiredo
Oppelt, P.
da Cunha Junior, G. F.
Franke, F. A.
Tseng, J.
Joshi, A. J.
McCarthy, J.
Sidi, Y.
Gumuscu, B.
Naicker, N.
de Castro, G., Jr.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E3 - E4
[8] Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti-PD-1 therapy: MASTERKEY-115.
Gastman, Brian
Robert, Caroline
Gogas, Helen
Rutkowski, Piotr
Long, Georgina V.
Chaney, Marya F.
Joshi, Harshada
Lin, Yu-Lin
Snyder, Wendy
Chesney, Jason Alan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
Cohen, E. E.
Harrington, K. J.
Le Tourneau, C.
Dinis, J.
Licitra, L.
Ahn, M-J.
Soria, A.
Machiels, J-P.
Mach, N.
Mehra, R.
Burtness, B.
Wang, Y.
Tuozzo, A. J.
Swaby, R.
Soulieres, D.
ANNALS OF ONCOLOGY, 2017, 28
[10] Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Rischin, Danny
Harrington, Kevin J.
Greil, Richard
Soulieres, Denis
Tahara, Makoto
de Castro, Gilberto
Psyrri, Amanda
Baste, Neus
Neupane, Prakash C.
Bratland, Ase
Fuereder, Thorsten
Hughes, Brett Gordon Maxwell
Mesia, Ricard
Ngamphaiboon, Nuttapong
Rordorf, Tamara
Ishak, Wan Zamaniah Wan
Zhang, Yayan
Jin, Fan
Gumuscu, Burak
Burtness, Barbara
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →